On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Saturday, March 11, 2023

Critical Dates after NDA/BLA submission: Filing Date (Day 1), Day 14, Day 60, Day 74, and PDUFA date

›
After the NDA/BLA is submitted to FDA, the FDA review clock starts. There are several critical dates relevant to the applicant (the sponsor)...
3 comments:
Friday, March 03, 2023

Risk of Stopping Trial Early for Treatment Benefit - Story of Veru's Sabizabulin for Treatment of Covid

›
Today, we learned that FDA declined to approve the emergency use authorization (EUA) for Veru's sabizabulin for the treatment of Covid. ...
2 comments:
Tuesday, February 21, 2023

Analysis of Data from Open-Label Extension (OLE) Study

›
In the previous article, the open-label extension (OLE) study was discussed. The OLE study is usually designed as a separate study from the ...
Monday, February 20, 2023

Open-Label Extension (OLE) Study

›
I asked OpenGPT to write a blog article about the open-label extension study and got the following response. The contents from OpenGPT seem ...
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.